Spanish health technology firm Biorce has raised $52.5 million in a Series A funding round aimed at expanding the global deployment of its artificial intelligence clinical trial platform. The investment round features participation from TZR Capital, Endeavour Catalyst, Norrsken VC, and Mustard Seed Maze.
The funds will be used to enhance Biorce’s AI-driven solutions that optimize clinical trial processes, improving efficiency and patient outcomes. This expansion supports the company’s goal of transforming how clinical trials are conducted worldwide.
**Why this matters**
Clinical trials are essential for developing new medical treatments, but they often face challenges such as patient recruitment and data management. Biorce’s AI technology aims to address these issues by streamlining trial operations, potentially accelerating drug development and reducing costs. This investment highlights growing interest in leveraging AI to improve healthcare research.
Source: NewsData